Compounds > caffeine

caffeine and ticagrelor

caffeine has been researched along with ticagrelor in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Braun, OÖ; Christersson, C; Grove, EL; Halvorsen, S; James, SK; Lindholm, D; Storey, RF; Varenhorst, C1
Andersson, J; Braun, OÖ; Heller, S; Henriksson, P; James, S; Lauermann, J; Lindholm, D; Öhagen, P; Varenhorst, C1
Aylward, P; Bhatt, DL; Bonaca, MP; Dellborg, M; Furtado, RHM; Goto, S; Gurmu, Y; Isaza, D; Johanson, P; Kamensky, G; Magnani, G; Nicolau, JC; Steg, PG; Storey, RF; Venkateswaran, RV1

Trials

3 trial(s) available for caffeine and ticagrelor

ArticleYear
Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.
    American heart journal, 2015, Volume: 170, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Caffeine; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Electrocardiography; Purinergic P1 Receptor Antagonists; Purinergic P2Y Receptor Antagonists; Ticagrelor

2015
Caffeine and incidence of dyspnea in patients treated with ticagrelor.
    American heart journal, 2018, Volume: 200

    Topics: Adenosine; Aged; Caffeine; Drug Monitoring; Dyspnea; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Reported Outcome Measures; Purinergic P2Y Receptor Antagonists; Ticagrelor

2018
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
    Journal of the American Heart Association, 2020, 05-18, Volume: 9, Issue:10

    Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Time Factors; Treatment Outcome

2020